Regardless of sample type (peripheral blood or bone marrow), RAF1 showed a 34.5-fold increased expression in the AML group compared to the control group, demonstrating high diagnostic value as a biomarker for AML. This evidence concerns the gene RAF1 and acute myeloid leukemia.